Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: Findings from CALGB 89803

Kimmie Ng*, Jeffrey A. Meyerhardt, Jennifer A. Chan, Donna Niedzwiecki, Donna R. Hollis, Leonard B. Saltz, Robert J. Mayer, Al B. Benson, Paul L. Schaefer, Renaud Whittom, Alexander Hantel, Richard M. Goldberg, Charles S. Fuchs

*Corresponding author for this work

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose: Multivitamin use is widespread in the United States, especially among patients with cancer. However, the influence of multivitamin supplementation on cancer recurrence and death after a curative resection of colon cancer is unknown. Patients and Methods: We conducted a prospective, observational study of 1,038 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on multivitamin use during and 6 months after adjuvant chemotherapy. Patients were observed until March 2009 for disease recurrence and death. To minimize bias by occult recurrence, we excluded patients who recurred or died within 90 days of their multivitamin assessment. Results: Among 1,038 patients, 518 (49.9%) reported multivitamin use during adjuvant chemotherapy. Compared with nonusers, the multivariate hazard ratio (HR) for disease-free survival was 0.94 (95% CI, 0.77 to 1.15) for patients who used multivitamins. Similarly, multivitamin use during adjuvant chemotherapy was not significantly associated with recurrence-free survival (multivariate HR, 0.93; 95% CI, 0.75 to 1.15) or overall survival (multivariate HR 0.92; 95% CI, 0.74 to 1.16). Multivitamin use reported 6 months after completion of adjuvant chemotherapy was also not associated with improved patient outcome, and consistent use both during and following adjuvant therapy conferred no benefit. Neither an increasing number of tablets nor increasing duration of use before cancer diagnosis was associated with cancer recurrence or mortality. Multivitamin use also did not improve the rates of grade 3 and higher GI toxicity. Conclusion: Multivitamin use during and after adjuvant chemotherapy was not significantly associated with improved outcomes in patients with stage III colon cancer.

Original languageEnglish (US)
Pages (from-to)4354-4363
Number of pages10
JournalJournal of Clinical Oncology
Volume28
Issue number28
DOIs
StatePublished - Oct 1 2010

Fingerprint

Colonic Neoplasms
Recurrence
Adjuvant Chemotherapy
Survival
Neoplasms
Tablets
Disease-Free Survival
Observational Studies
Prospective Studies
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ng, Kimmie ; Meyerhardt, Jeffrey A. ; Chan, Jennifer A. ; Niedzwiecki, Donna ; Hollis, Donna R. ; Saltz, Leonard B. ; Mayer, Robert J. ; Benson, Al B. ; Schaefer, Paul L. ; Whittom, Renaud ; Hantel, Alexander ; Goldberg, Richard M. ; Fuchs, Charles S. / Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer : Findings from CALGB 89803. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 28. pp. 4354-4363.
@article{d35c47981cf04398ae61fbc13cc00c0f,
title = "Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: Findings from CALGB 89803",
abstract = "Purpose: Multivitamin use is widespread in the United States, especially among patients with cancer. However, the influence of multivitamin supplementation on cancer recurrence and death after a curative resection of colon cancer is unknown. Patients and Methods: We conducted a prospective, observational study of 1,038 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on multivitamin use during and 6 months after adjuvant chemotherapy. Patients were observed until March 2009 for disease recurrence and death. To minimize bias by occult recurrence, we excluded patients who recurred or died within 90 days of their multivitamin assessment. Results: Among 1,038 patients, 518 (49.9{\%}) reported multivitamin use during adjuvant chemotherapy. Compared with nonusers, the multivariate hazard ratio (HR) for disease-free survival was 0.94 (95{\%} CI, 0.77 to 1.15) for patients who used multivitamins. Similarly, multivitamin use during adjuvant chemotherapy was not significantly associated with recurrence-free survival (multivariate HR, 0.93; 95{\%} CI, 0.75 to 1.15) or overall survival (multivariate HR 0.92; 95{\%} CI, 0.74 to 1.16). Multivitamin use reported 6 months after completion of adjuvant chemotherapy was also not associated with improved patient outcome, and consistent use both during and following adjuvant therapy conferred no benefit. Neither an increasing number of tablets nor increasing duration of use before cancer diagnosis was associated with cancer recurrence or mortality. Multivitamin use also did not improve the rates of grade 3 and higher GI toxicity. Conclusion: Multivitamin use during and after adjuvant chemotherapy was not significantly associated with improved outcomes in patients with stage III colon cancer.",
author = "Kimmie Ng and Meyerhardt, {Jeffrey A.} and Chan, {Jennifer A.} and Donna Niedzwiecki and Hollis, {Donna R.} and Saltz, {Leonard B.} and Mayer, {Robert J.} and Benson, {Al B.} and Schaefer, {Paul L.} and Renaud Whittom and Alexander Hantel and Goldberg, {Richard M.} and Fuchs, {Charles S.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1200/JCO.2010.28.0362",
language = "English (US)",
volume = "28",
pages = "4354--4363",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

Ng, K, Meyerhardt, JA, Chan, JA, Niedzwiecki, D, Hollis, DR, Saltz, LB, Mayer, RJ, Benson, AB, Schaefer, PL, Whittom, R, Hantel, A, Goldberg, RM & Fuchs, CS 2010, 'Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: Findings from CALGB 89803', Journal of Clinical Oncology, vol. 28, no. 28, pp. 4354-4363. https://doi.org/10.1200/JCO.2010.28.0362

Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer : Findings from CALGB 89803. / Ng, Kimmie; Meyerhardt, Jeffrey A.; Chan, Jennifer A.; Niedzwiecki, Donna; Hollis, Donna R.; Saltz, Leonard B.; Mayer, Robert J.; Benson, Al B.; Schaefer, Paul L.; Whittom, Renaud; Hantel, Alexander; Goldberg, Richard M.; Fuchs, Charles S.

In: Journal of Clinical Oncology, Vol. 28, No. 28, 01.10.2010, p. 4354-4363.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer

T2 - Findings from CALGB 89803

AU - Ng, Kimmie

AU - Meyerhardt, Jeffrey A.

AU - Chan, Jennifer A.

AU - Niedzwiecki, Donna

AU - Hollis, Donna R.

AU - Saltz, Leonard B.

AU - Mayer, Robert J.

AU - Benson, Al B.

AU - Schaefer, Paul L.

AU - Whittom, Renaud

AU - Hantel, Alexander

AU - Goldberg, Richard M.

AU - Fuchs, Charles S.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Purpose: Multivitamin use is widespread in the United States, especially among patients with cancer. However, the influence of multivitamin supplementation on cancer recurrence and death after a curative resection of colon cancer is unknown. Patients and Methods: We conducted a prospective, observational study of 1,038 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on multivitamin use during and 6 months after adjuvant chemotherapy. Patients were observed until March 2009 for disease recurrence and death. To minimize bias by occult recurrence, we excluded patients who recurred or died within 90 days of their multivitamin assessment. Results: Among 1,038 patients, 518 (49.9%) reported multivitamin use during adjuvant chemotherapy. Compared with nonusers, the multivariate hazard ratio (HR) for disease-free survival was 0.94 (95% CI, 0.77 to 1.15) for patients who used multivitamins. Similarly, multivitamin use during adjuvant chemotherapy was not significantly associated with recurrence-free survival (multivariate HR, 0.93; 95% CI, 0.75 to 1.15) or overall survival (multivariate HR 0.92; 95% CI, 0.74 to 1.16). Multivitamin use reported 6 months after completion of adjuvant chemotherapy was also not associated with improved patient outcome, and consistent use both during and following adjuvant therapy conferred no benefit. Neither an increasing number of tablets nor increasing duration of use before cancer diagnosis was associated with cancer recurrence or mortality. Multivitamin use also did not improve the rates of grade 3 and higher GI toxicity. Conclusion: Multivitamin use during and after adjuvant chemotherapy was not significantly associated with improved outcomes in patients with stage III colon cancer.

AB - Purpose: Multivitamin use is widespread in the United States, especially among patients with cancer. However, the influence of multivitamin supplementation on cancer recurrence and death after a curative resection of colon cancer is unknown. Patients and Methods: We conducted a prospective, observational study of 1,038 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial. Patients reported on multivitamin use during and 6 months after adjuvant chemotherapy. Patients were observed until March 2009 for disease recurrence and death. To minimize bias by occult recurrence, we excluded patients who recurred or died within 90 days of their multivitamin assessment. Results: Among 1,038 patients, 518 (49.9%) reported multivitamin use during adjuvant chemotherapy. Compared with nonusers, the multivariate hazard ratio (HR) for disease-free survival was 0.94 (95% CI, 0.77 to 1.15) for patients who used multivitamins. Similarly, multivitamin use during adjuvant chemotherapy was not significantly associated with recurrence-free survival (multivariate HR, 0.93; 95% CI, 0.75 to 1.15) or overall survival (multivariate HR 0.92; 95% CI, 0.74 to 1.16). Multivitamin use reported 6 months after completion of adjuvant chemotherapy was also not associated with improved patient outcome, and consistent use both during and following adjuvant therapy conferred no benefit. Neither an increasing number of tablets nor increasing duration of use before cancer diagnosis was associated with cancer recurrence or mortality. Multivitamin use also did not improve the rates of grade 3 and higher GI toxicity. Conclusion: Multivitamin use during and after adjuvant chemotherapy was not significantly associated with improved outcomes in patients with stage III colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=78049428751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049428751&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.28.0362

DO - 10.1200/JCO.2010.28.0362

M3 - Article

C2 - 20805450

AN - SCOPUS:78049428751

VL - 28

SP - 4354

EP - 4363

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 28

ER -